Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone
Authors:
Open Access
- 1 September 2018
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 4 (8) , 830-832
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Severe persistent injection site reactions after subcutaneous 2′-O-methyl phosphorothioate oligonucleotide therapy for Duchenne muscular dystrophyNeuromuscular Disorders, 2018
- Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting SystemDiabetes Spectrum, 2015
- Exenatide-Induced Eosinophil-Rich Granulomatous PanniculitisThe American Journal of Dermatopathology, 2015
- Exenatide-Induced Eosinophilic Sclerosing Lipogranuloma at the Injection SiteThe American Journal of Dermatopathology, 2014
- Eosinophil‐rich granulomatous panniculitis caused by exenatide injectionJournal of Cutaneous Pathology, 2013
- Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION TrialsPostgraduate Medicine, 2013
- Evolution of Exenatide as a Diabetes TherapeuticCurrent Diabetes Reviews, 2013
- Encapsulation of Exenatide in Poly-( d,l -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 DiabetesDiabetes Technology & Therapeutics, 2011
- Exenatide: a review from pharmacology to clinical practiceDiabetes, Obesity and Metabolism, 2009
- Vitamin B12-Associated Localized Scleroderma and Its TreatmentDermatologic Surgery, 2004